New Drug Could Let Some Rectal Cancer Patients Skip Chemotherapy, Radiation and Surgery

The US FDA approved dostarlimab-gxly (Jemperli) for certain adults with stage II or III rectal cancer displaying a specific tumor DNA repair defect, showing early results where nearly 75% of patients avoided surgery, radiation, or chemotherapy after more than two years.

This Wire brief sits within Fusion42's coverage of Biotech, and 15 sources have reported it between 19 Oct 2026 and 25 Oct 2026.